So far this year, the psychedelic industry has been a bright spot in what has been a challenging market. We like to compare the emergence of the psychedelic industry to the cannabis industry and believe that it is an opportunity to be aware of.
Many of the companies that are focused on the psychedelic industry are in process of developing treatments for debilitating mental illnesses. Although researchers have only scratched the surface when it comes to understanding the medical benefits that are associated with psychedelics, the initial data has been overwhelmingly positive, and we find this to be significant.
We have conducted significant due diligence on Numinus which aims to be one the first publicly traded companies licensed to test, sell and deliver psychedelic therapies. The company has been nothing short of an execution story and we are favorable on the direction that the management team is taking the business.
Today, Numinus will commence trading on the TSXV and will trade under the symbol NUMI.
We believe that Numinus represents a multi-faceted growth story and is an opportunity to be aware of. The company’s platform includes a testing and research facility that can leverage the development of psychedelic therapies to supplement existing options in addressing mental illness, addictions, and post-traumatic-stress disorder (PTSD). Numinus also has an established and fully integrated therapy and wellness center model that it plans to scale globally.
Numinus is led by a management team that has a proven track record of success in a number of industry and we find this to be of importance. The management team plans to fund growth through an existing revenue generating cannabis business and we find this to be an attractive aspect of the story.
Last summer, Numinus was issued a Dealer’s license under the Controlled Substances Act that allows it to play a key role in the areas of psychedelic substances research, testing, and global distribution. The company is approved to test, possess, buy and sell MDMA, psilocybin, psilocin, DMT and mescaline. Going forward, Numinus plans to expand and is in the process of amending its license to include activities such as R&D, import/export and packaging/labelling.
Numinus plans on becoming the leading psychedelics drugs marketing and distribution company and is an opportunity to be closely following. If you are interested in learning more about Numinus, please send an email to email@example.com to be added to our distribution list.
Pursuant to an agreement between StoneBridge Partners LLC and Numinus Wellness Inc.. (NUMI) we have been hired for a period of 180 days beginning April 15, 2020 and ending October 15, 2020 to publicly disseminate information about (NUMI) including on the Website and other media including Facebook and Twitter. We are being paid $7,500 per month (NUMI) for or were paid “0” shares of restricted common shares. We own zero shares of (NUMI), which we purchased in the open market. We plan to sell the “ZERO” shares of (NUMI) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (NUMI) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.